Beiersdorf Aktiengesellschaft
Explore by topic
5-year stock timeline
2026-08-03 — H1 2026 results
Group sales declined 3.5% organically to €4.95bn in the first half. Consumer sales fell 4.0% on an organic basis. EBIT excluding special factors reached €768m, with a margin of 15.5%. Management acknowledged ongoing pressure on NIVEA and maintained cautious near-term guidance, though continued to emphasize Derma strength [1][14].
Investor sentiment shifted toward a defensive posture. Derma emerged as the primary growth driver and structural counterweight to NIVEA's weakness. The market began pricing in a multi-quarter NIVEA rebalancing cycle rather than a near-term recovery. Share performance reflected this caution, trading sideways to lower from spring levels as investors awaited evidence of NIVEA stabilization [1][14].
2026-04-21 — Q1 2026 quarterly statement
Group organic sales contracted 4.6% in the first quarter, with Consumer down 4.7%. Management reiterated full-year guidance and flagged rebalancing initiatives for NIVEA [10][12].
The cautious tone reinforced investor perception of 2026 as an operational consolidation year. Derma demonstrated resilience while legacy NIVEA required repositioning and capital investment. Investor focus narrowed to product mix and margin performance rather than headline sales growth. Share trading showed a short-term downtrend punctuated by relief rallies tied to Derma updates or margin beats [10][12].
2026-03-02 — Full-year results for 2025
Group organic growth reached 2.4% for the full year, with Consumer organic growth at 2.5%. Derma recorded double-digit growth for the fifth consecutive year. EBIT margin excluding special factors rose to approximately 14.0%, and EPS excluding special factors increased [3][7].
The results reinforced the narrative of Beiersdorf as a resilient consumer staples compounder with Derma becoming an increasingly material high-growth segment. Investors responded positively to evidence of margin expansion and dividend stability, though near-term caution about NIVEA's mid-cycle variability persisted. Share performance rallied from 2025 H1 levels into early 2026 on the back of organic growth beats, then plateaued as 2026 guidance tempered expectations [3][7].
2025-04-17 — Annual General Meeting and dividend decision
The AGM approved a dividend of €1.00 per share for FY2024, an increase from the prior €0.70 level. The decision signaled management confidence in cash flow generation and a shareholder-friendly capital allocation approach [9][6].
The dividend increase supported a value and income-oriented investor base and reduced near-term downside concerns. Share performance steadied through 2025 as improved investor interest coincided with the dividend lift [9][6].
2024 — Derma outperformance and margin progression
FY2024 results showed group sales of approximately €9.45bn with operating margin expansion (EBIT margin excluding special factors trending from 13.4% toward 13.9% into 2025). Derma contribution increased while NIVEA underwent repositioning investment [7].
The results reinforced a longer-term thesis of portfolio rebalancing. Investors increasingly characterized Beiersdorf as a mid-single-digit sales grower with expanding margins driven by product mix and cost discipline. Some labeled it a defensive compounder with targeted upside if NIVEA revived. Share performance reflected this view, trending higher through much of 2024 into early 2025 [7].
2023 — Post-pandemic normalization and strategic Derma acceleration
2023 reporting emphasized normalization after pandemic distortions, margin recovery, and strategic acceleration of Derma brands. EPS and margin metrics showed year-on-year improvement [7].
Market perception shifted from cyclical recovery to structural portfolio reweighting. Management credibility improved as cost measures and brand investments translated to better profitability. Many investors began valuing the stock as a stable consumer compounder rather than a legacy brand holder. Share performance showed a gradual uptrend through 2023 with periodic pullbacks on macro headlines [7].
2022 — Inflation pressures and margin defense
2022 results reflected cost and raw-material inflation. Management implemented price increases and efficiency measures while organic growth resumed, though margins faced pressure in parts of the business [7].
Investor sentiment was mixed. Some viewed Beiersdorf as weathering inflation through pricing and mix; others questioned margin resilience and consumer recovery speed. Share performance remained rangebound to slightly recovery-oriented as markets digested inflation impacts and company mitigation steps [7].
2021 — Early recovery and dividend restoration
2021 showed recovery from COVID-19 troughs in certain channels. FY2021 EPS and dividend were restored to pre-shock levels at €0.70, and management communicated multi-year growth ambition and efficiency plans [7][6].
Investor perception remained mixed between recovery play and defensive staple. Brand strength was appreciated, though structural growth questions persisted beyond steady cash flows. The stock was often characterized as a value and dividend holding. Share performance reflected this, moving from 2020 lows into a consolidation range through 2021 [7][6].
Key risks and downside factors
Beiersdorf operates as a global consumer goods company with two distinct business pillars: mass and prestige skincare through brands like Nivea, Eucerin, and La Prairie, alongside industrial adhesive tapes under the tesa banner. Its competitive landscape includes large multinational players such as L'Oréal, Unilever, P&G, Estée Lauder, and Shiseido, as well as regional and independent skincare operators. This competitive density creates persistent pressure on pricing, distribution access, and the pace of innovation required to maintain relevance. The business carries several material risks worth monitoring. Heavy reliance on a concentrated brand portfolio leaves limited room for underperformance in any single asset. Larger competitors possess cost advantages that can compress margins, particularly in price-sensitive segments. Supply chain disruptions and input cost volatility remain structural exposures in a manufacturing-dependent business. Regulatory and product-safety liabilities carry both financial and reputational weight. Currency fluctuations and macroeconomic sensitivity in emerging markets introduce earnings volatility that's difficult to hedge cleanly, especially given the geographic distribution of sales exposure.
- Brand concentration and competitive pricing pressure create meaningful exposure. Heavy reliance on Nivea and a handful of major brands means revenue and margins remain vulnerable to competitor promotions and erosion of brand share.
- Raw material and supply-chain disruption pose ongoing margin pressure. Commodity prices, packaging costs, and transport expenses remain volatile, while dependence on third-party manufacturers introduces additional exposure to cost shocks that can compress profitability materially.
- Regulatory shifts, product-safety issues, and litigation pose material risks. Changes to cosmetic regulations, adverse product claims, or recalls in significant markets can result in fines, remediation expenses, and reputational harm.
- Geographic and currency exposure creates material risk: significant sales in emerging markets expose the company to foreign exchange volatility, which can compress reported sales and profits, while regional macroeconomic downturns tend to hit harder when currency headwinds are present [8], [3].
Competitive landscape
Beiersdorf operates as a global consumer-care company with two distinct business pillars: skin care brands including Nivea, Eucerin, and La Prairie, alongside industrial adhesive solutions under tesa. The company faces competition from large multinational groups spanning mass-market, prestige, and dermocosmetic segments, as well as from regional and independent players in both consumer and industrial categories. Competitive dynamics center on scale advantages, research and development capabilities, distribution reach across retail and e-commerce channels, and pricing power. The business carries exposure to several material risks. Product quality, regulatory compliance, and brand reputation represent ongoing operational concerns. Input cost inflation and foreign exchange movements create margin pressure. Competitor innovation and aggressive pricing strategies demand continuous investment and market responsiveness. Supply chain resilience and the pace of digital transformation execution present additional operational challenges that could affect performance if not managed effectively.
| Company | Ticker |
|---|---|
| The Procter & Gamble Company | PG.NYSE |
| The Estée Lauder Companies Inc. | EL.NYSE |
| Johnson & Johnson | JNJ.NYSE |
| Henkel AG & Co. KGaA | HEN3.XETRA |
| 3M Company | MMM.NYSE |
| Coty Inc. | COTY.NYSE |
Private competitors
- Barbara Sturm (Dr. Barbara Sturm GmbH)
- Many indie / DTC skincare brands (collective — e.g., consumer‑direct niche brands across markets)
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialPerformance Figures of Beiersdorf Aktiengesellschaft
Relative Performance vs Benchmarks
| Period | Beiersdorf Aktiengesellschaft | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | -1.36% | -7.84% | -5.81% |
| 3M | +11.50% | +2.73% | +6.13% |
| 6M | -25.10% | -30.87% | -39.40% |
| 1Y | -22.01% | -30.55% | -44.00% |
| 3Y | -32.78% | -101.44% | -117.48% |
| 5Y | -22.63% | -88.69% | -109.70% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 18.2 | 1.8 | 1.9 | 16.3 |
| 1Y ago | 13.7 | 1.1 | 2.6 | 10.9 |
| 3Y ago | 22.5 | 2.0 | 3.4 | 29.2 |
| 5Y ago | 24.6 | 2.2 | 3.6 | 13.2 |
Frequently Asked Questions
Where is the Beiersdorf Aktiengesellschaft stock traded?
What does Beiersdorf Aktiengesellschaft do?
What are the key metrics for BEI.XETRA?
How has Beiersdorf Aktiengesellschaft's stock price performed?
How is BEI.XETRA valued?
Does BEI.XETRA pay dividends?
What are the key risks when investing in BEI.XETRA?
- Brand concentration and competitive pricing pressure create meaningful exposure. Heavy reliance on Nivea and a handful of major brands means revenue and margins remain vulnerable to competitor promotions and erosion of brand share.
- Raw material and supply-chain disruption pose ongoing margin pressure. Commodity prices, packaging costs, and transport expenses remain volatile, while dependence on third-party manufacturers introduces additional exposure to cost shocks that can compress profitability materially.
- Regulatory shifts, product-safety issues, and litigation pose material risks. Changes to cosmetic regulations, adverse product claims, or recalls in significant markets can result in fines, remediation expenses, and reputational harm.
- Geographic and currency exposure creates material risk: significant sales in emerging markets expose the company to foreign exchange volatility, which can compress reported sales and profits, while regional macroeconomic downturns tend to hit harder when currency headwinds are present [8, 3, 21].
Who are the main competitors of Beiersdorf Aktiengesellschaft?
- The Procter & Gamble Company (PG.NYSE)
- The Estée Lauder Companies Inc. (EL.NYSE)
- Johnson & Johnson (JNJ.NYSE)
- Henkel AG & Co. KGaA (HEN3.XETRA)
- 3M Company (MMM.NYSE)
- Coty Inc. (COTY.NYSE)
When does Beiersdorf Aktiengesellschaft report earnings?
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 1.00 EUR | 1.35% | 0.88% |
| 2025 | 1.00 EUR | 0.84% | |
| 2024 | 1.00 EUR | 0.74% | |
| 2023 | 0.70 EUR | 0.57% | |
| 2022 | 0.70 EUR | 0.74% | |
| 2021 | 0.70 EUR | 0.78% | |
| 2020 | 0.70 EUR | 0.74% | |
| 2019 | 0.70 EUR | 0.76% | |
| 2018 | 0.70 EUR | 0.76% | |
| 2017 | 0.70 EUR | 0.77% | |
| 2016 | 0.70 EUR | 0.88% | |
| 2015 | 0.70 EUR | 0.87% | |
| 2014 | 0.70 EUR | 0.99% | |
| 2013 | 0.70 EUR | 1.03% | |
| 2012 | 0.70 EUR | 1.33% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 9.85B | 9.85B | 9.45B | 8.80B | 7.63B |
| Operating income (EBIT) | 1.35B | 1.30B | 1.10B | 1.22B | 980.00M |
| Net income | 939.00M | 912.00M | 736.00M | 755.00M | 638.00M |
| Free cash flow | 373.00M | 794.00M | 424.00M | 249.00M | 580.00M |
| Total assets | 12.85B | 13.01B | 12.63B | 12.35B | 11.30B |
| Equity | 8.60B | 8.47B | 8.32B | 7.79B | 6.87B |
| Net debt | -983.00M | -941.00M | -1.03B | -722.00M | -757.00M |
PWP Leeway UG (haftungsbeschränkt)
